vs
Side-by-side financial comparison of Coherus Oncology, Inc. (CHRS) and R F INDUSTRIES LTD (RFIL). Click either name above to swap in a different company.
R F INDUSTRIES LTD is the larger business by last-quarter revenue ($22.7M vs $12.7M, roughly 1.8× Coherus Oncology, Inc.). R F INDUSTRIES LTD runs the higher net margin — 0.8% vs -295.3%, a 296.0% gap on every dollar of revenue. On growth, Coherus Oncology, Inc. posted the faster year-over-year revenue change (64.9% vs 22.9%). Over the past eight quarters, R F INDUSTRIES LTD's revenue compounded faster (29.8% CAGR vs -47.0%).
Coherus Oncology, Inc. is a commercial-stage biopharmaceutical company focused on developing, manufacturing and commercializing affordable oncology treatments, including FDA-approved biosimilars and novel targeted immuno-oncology therapies. Its core market is North America, serving patients with solid tumors and hematological malignancies to expand access to life-saving cancer care.
Tootsie Roll Industries is an American manufacturer of confectionery based in Chicago, Illinois. Its best-known products include the namesake Tootsie Rolls and Tootsie Pops. Tootsie Roll Industries currently markets its brands internationally in Canada, Mexico, and over 75 other countries.
CHRS vs RFIL — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.7M | $22.7M |
| Net Profit | $-37.6M | $173.0K |
| Gross Margin | 68.3% | 36.8% |
| Operating Margin | -359.9% | 4.0% |
| Net Margin | -295.3% | 0.8% |
| Revenue YoY | 64.9% | 22.9% |
| Net Profit YoY | 25.7% | 172.7% |
| EPS (diluted) | $-0.34 | $0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.7M | $22.7M | ||
| Q3 25 | $11.6M | $19.8M | ||
| Q2 25 | $10.3M | $18.9M | ||
| Q1 25 | — | $19.2M | ||
| Q4 24 | — | $18.5M | ||
| Q3 24 | — | $16.8M | ||
| Q2 24 | $10.3M | $16.1M | ||
| Q1 24 | — | $13.5M |
| Q4 25 | $-37.6M | $173.0K | ||
| Q3 25 | $-35.5M | $392.0K | ||
| Q2 25 | $297.8M | $-245.0K | ||
| Q1 25 | — | $-245.0K | ||
| Q4 24 | — | $-238.0K | ||
| Q3 24 | — | $-705.0K | ||
| Q2 24 | $-12.9M | $-4.3M | ||
| Q1 24 | — | $-1.4M |
| Q4 25 | 68.3% | 36.8% | ||
| Q3 25 | 67.8% | 34.0% | ||
| Q2 25 | 66.9% | 31.5% | ||
| Q1 25 | — | 29.8% | ||
| Q4 24 | — | 31.3% | ||
| Q3 24 | — | 29.5% | ||
| Q2 24 | 82.4% | 29.9% | ||
| Q1 24 | — | 24.5% |
| Q4 25 | -359.9% | 4.0% | ||
| Q3 25 | -383.1% | 3.6% | ||
| Q2 25 | -443.6% | 0.6% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | -2.5% | ||
| Q2 24 | -384.9% | -2.6% | ||
| Q1 24 | — | -15.5% |
| Q4 25 | -295.3% | 0.8% | ||
| Q3 25 | -307.1% | 2.0% | ||
| Q2 25 | 2903.9% | -1.3% | ||
| Q1 25 | — | -1.3% | ||
| Q4 24 | — | -1.3% | ||
| Q3 24 | — | -4.2% | ||
| Q2 24 | -125.5% | -26.7% | ||
| Q1 24 | — | -10.1% |
| Q4 25 | $-0.34 | $0.01 | ||
| Q3 25 | $-0.31 | $0.04 | ||
| Q2 25 | $2.57 | $-0.02 | ||
| Q1 25 | — | $-0.02 | ||
| Q4 24 | — | $-0.02 | ||
| Q3 24 | — | $-0.07 | ||
| Q2 24 | $-0.11 | $-0.41 | ||
| Q1 24 | — | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $172.1M | $5.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $61.0M | $35.2M |
| Total Assets | $258.3M | $73.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $172.1M | $5.1M | ||
| Q3 25 | $191.7M | $3.0M | ||
| Q2 25 | $237.6M | $3.6M | ||
| Q1 25 | — | $1.3M | ||
| Q4 24 | — | $839.0K | ||
| Q3 24 | — | $1.8M | ||
| Q2 24 | $159.2M | $1.4M | ||
| Q1 24 | — | $4.5M |
| Q4 25 | $61.0M | $35.2M | ||
| Q3 25 | $87.8M | $34.8M | ||
| Q2 25 | $119.8M | $34.2M | ||
| Q1 25 | — | $34.2M | ||
| Q4 24 | — | $34.1M | ||
| Q3 24 | — | $34.1M | ||
| Q2 24 | $-84.1M | $34.6M | ||
| Q1 24 | — | $38.7M |
| Q4 25 | $258.3M | $73.0M | ||
| Q3 25 | $516.5M | $73.2M | ||
| Q2 25 | $439.5M | $72.7M | ||
| Q1 25 | — | $70.4M | ||
| Q4 24 | — | $71.0M | ||
| Q3 24 | — | $71.9M | ||
| Q2 24 | $674.9M | $72.8M | ||
| Q1 24 | — | $79.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-19.7M | $2.1M |
| Free Cash FlowOCF − Capex | — | $2.0M |
| FCF MarginFCF / Revenue | — | 9.0% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | — | 12.13× |
| TTM Free Cash FlowTrailing 4 quarters | — | $4.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-19.7M | $2.1M | ||
| Q3 25 | $-46.3M | $-311.0K | ||
| Q2 25 | $-46.6M | $2.2M | ||
| Q1 25 | — | $601.0K | ||
| Q4 24 | — | $-244.0K | ||
| Q3 24 | — | $2.4M | ||
| Q2 24 | $59.7M | $197.0K | ||
| Q1 24 | — | $840.0K |
| Q4 25 | — | $2.0M | ||
| Q3 25 | — | $-419.0K | ||
| Q2 25 | — | $2.2M | ||
| Q1 25 | — | $574.0K | ||
| Q4 24 | — | $-418.0K | ||
| Q3 24 | — | $2.1M | ||
| Q2 24 | — | $28.0K | ||
| Q1 24 | — | $697.0K |
| Q4 25 | — | 9.0% | ||
| Q3 25 | — | -2.1% | ||
| Q2 25 | — | 11.4% | ||
| Q1 25 | — | 3.0% | ||
| Q4 24 | — | -2.3% | ||
| Q3 24 | — | 12.6% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 5.2% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 0.5% | ||
| Q2 25 | — | 0.2% | ||
| Q1 25 | — | 0.1% | ||
| Q4 24 | — | 0.9% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | — | 1.0% | ||
| Q1 24 | — | 1.1% |
| Q4 25 | — | 12.13× | ||
| Q3 25 | — | -0.79× | ||
| Q2 25 | -0.16× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CHRS
| Toripalimab | $12.4M | 97% |
| Other | $388.0K | 3% |
RFIL
| US | $20.9M | 92% |
| Non Us | $1.8M | 8% |
